Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight
PR Newswire —
The CSPC market is poised for strong, double-digit growth, driven by aging demographics, improved screening, and strategic treatment advancements. While cost and access challenges persist, emerging therapies such as TRUQAP (AstraZeneca), TAVT-45 (Tavanta Therapeutics), Saruparib...